1. Field of the Invention
The present invention relates generally to medical methods and apparatus. More particularly, the present invention relates to methods and apparatus for the assessment and treatment of lung diseases, such as chronic obstructive pulmonary disease, by detecting the status of the disease and determining an appropriate treatment protocol.
Chronic obstructive pulmonary disease (COPD) is a significant medical problem affecting sixteen million people or about 6% of the U.S. population. Specific diseases in this group include chronic bronchitis, asthmatic bronchitis, and emphysema. While a number of therapeutic interventions are used and have been proposed, none are completely effective, and COPD remains the fourth most common cause of death in the United States. Thus, improved and alternative treatments and therapies would be of significant benefit.
Management of COPD is largely medical and infrequently surgical. Initially, exercise and smoking cessation are encouraged. Medications including bronchodilators and anti-inflammatories are routinely prescribed. Pulmonary rehabilitation has been shown to improve quality of life and sense of well being. Long term oxygen is generally reserved for the more severely affected patients.
Emphysema is a condition of the lung characterized by the abnormal permanent enlargement of the airspaces distal to the terminal bronchiole, accompanied by the destruction of their walls. It is known that emphysema and other pulmonary diseases reduce the ability of part of the lungs to fully expel air during the exhalation phase of the breathing cycle. During breathing, the diseased portion of the lung does not fully recoil due to the diseased lung tissue being less elastic than healthy tissue. Consequently, as the airways normally held open by the elastic pull of the lungs become floppy and the diseased lung tissue exerts a diminished driving force during exhalation, the airways close prematurely resulting in air trapping and hyperinflation.
In addition, hyper-expanded lung tissue occupies more of the pleural space than healthy lung tissue. In most cases, only a part of the lung is diseased while the remaining portion is relatively healthy and therefore still able to efficiently carry out oxygen exchange. By taking up more of the pleural space, the hyper-expanded lung tissue reduces the space available to accommodate the healthy, functioning lung tissue. As a result, the hyper-expanded lung tissue causes inefficient breathing by compressing the adjacent functional airways, alveolar units, and capillaries in relatively healthier lung tissue.
Lung function in patients suffering from some forms of COPD can be improved by reducing the effective lung volume, typically by resecting diseased portions of the lung. Resection of diseased portions of the lungs both promotes expansion of the non-diseased regions of the lung and decreases the portion of inhaled air which goes into the lungs but is unable to transfer oxygen to the blood. Accordingly, recruitment of previously compressed functional airways, alveolar units, and capillaries in relatively healthier lung is possible resulting in more gas exchange in addition to better matching of lung and chest wall dimensions. Lung reduction is conventionally performed in open chest or thoracoscopic procedures where the lung is resected, typically using stapling devices having integral cutting blades.
While effective in many cases, conventional lung volume reduction surgery (LVRS) is significantly traumatic to the patient, even when thoracoscopic procedures are employed. Such procedures often result in the unintentional removal of healthy lung tissue, and frequently leave perforations or other discontinuities in the lung which result in air leakage from the remaining lung. Even technically successful procedures can cause respiratory failure, pneumonia, and death. In addition, many older or compromised patients are not able to be candidates for these procedures.
As an alternative to LVRS, endobronchial volume reduction (EVR) uses endobronchially introduced devices which plug or otherwise isolate a diseased compartment from healthier regions of the lung in order to achieve volume reduction of the diseased compartment. Isolation devices may be implanted in the main airways feeding the diseased region of the lung, and volume reduction takes place via absorption atelectasis after implantation or via collapse by actively suctioning of the target compartment prior to implantation. These implanted isolation devices can be, for example, self-expanding occlusive stents that prevent air flow in both directions or one-way valves that allow flow in the exhalation direction only.
While a significant improvement over LVRS, EVR can have a limited therapeutic benefit when the treated region in the lung is exposed to collateral ventilation from adjacent regions. The lungs comprise a plurality of compartments, referred to as lung compartments or lobes, which are separated from one another by a double layer of enfolded reflections of visceral pleura, referred to as fissures. While the fissures which separate the compartments are typically impermeable, in patients suffering from COPD, the fissures are frequently incomplete, leaving a pathway for collateral airflow or inter-lobular collateral ventilation. Such collateral airflow can result in the intrusion of air into the isolated lung compartments treated by LVR, thus reducing or eliminating the desired volume reduction.
While collateral flow to diseased lung compartments can be detected, for example using the methods described in copending, commonly-owned U.S. patent application Ser. No. 11/296,591, filed on Dec. 7, 2005 (US 2006/0264772A1) and Ser. No. 11/550,660, filed on Oct. 18, 2006 (US 2007/0142742A1). While the use of these procedures can identify patents likely to benefit from EVR procedures, the need to perform a separate diagnostic procedure prior to a therapeutic procedure is time consuming, costly, and inconvenient for the patient.
For these reasons, it would be desirable to provide alternative and improved methods and apparatus for performing endobronchial volume reduction (EVR) and other lung therapies in an efficient and effective manner. In particular, it would be desirable to provide methods and apparatus which permit both the detection of collateral ventilation and subsequent treatment of diseased lung compartments in a single protocol where the treatment is completed only for those patients having no or an acceptable level of collateral ventilation. At least some of these objectives will be met by the inventions described hereinbelow.
2. Description of the Background Art
Exemplary methods for treating diseased lung compartments by isolating the diseased regions are described, for example, in U.S. Pat. No. 6,287,290; U.S. Pat. No. 6,679,264; U.S. Pat. No. 6,722,360; U.S. Pat. No. 7,011,094; and printed publication U.S. 2007/0005083. Methods for detecting collateral ventilation prior to treatment of diseased lung regions are described in patent publications U.S. 2006/0264772A1 and U.S. 2007/0142742A1, the full disclosures of which have been previously incorporated herein by reference.
The present invention provides improved methods and apparatus for treating targeted lung compartments, typically diseased lung compartments, in patients suffering from emphysema or other forms of COPD. The methods allow for both detecting collateral ventilation in the target lung compartment and for treating the target lung compartment in a single protocol, thus reducing the time and expense necessary for treating patients and providing a more convenient and acceptable therapy for the patient.
The methods utilize a catheter having a flow restrictive component connected thereto, typically at a distal end. The flow restrictive component is deployed in a main bronchus which feeds the target lung compartment while said component is connected to the catheter. While the target lung compartment remains isolated by the flow restrictive component, a determination is made of whether collateral ventilation exists in the target lung compartment. Any of the protocols described in published applications U.S. 2006/0264772 or U.S. 2007/0142742, both of which have been previously incorporated herein by reference, may be employed.
If it is determined that collateral ventilation is not present in the target lung compartment, the flow restrictive component may be detached from the catheter and left in place to effect a permanent isolation of the compartment to complete what is likely to be a successful LVR therapy. If, on the contrary, collateral ventilation is found to exist to a degree which would make successful LVR treatment unlikely, the flow restrictive component will be left attached to the catheter, and the catheter may be used to withdraw the flow restrictive element from the lung. The patient may then be treated by other therapies. By using the flow restrictive element both for the detection of collateral ventilation and for the optional treatment using EVR protocols, treatment time is reduced and the patient's comfort is increased.
The flow restrictive component may be the same as or similar to many components already described in the patent and medical literature. That is, a flow restrictive element may be intended to effect a complete blockage of flow into and out of the isolated lung compartment. Such blocking elements may be referred to as “occlusive stents,” and are described in commonly-assigned U.S. Pat. No. 6,527,761 and U.S. Pat. No. 6,997,918, the full disclosures of which are incorporated herein by reference. Alternatively, the flow restrictive elements may comprise a restrictor which includes a small orifice, small diameter tube, perforated membrane, densely braided structure, perimeter channel, or other fixed-resistance element which impedes flow, but allows a low flow in both directions. Such flow-permitting restrictors are referred to as “restrictor stents,” and are described in copending application Ser. No. 11/682,986, the full disclosure of which is incorporated herein by reference.
Regardless of whether an occlusive stent is used or a restrictive stent is used, it will usually be necessary that the flow restrictor provide for a flow path from the catheter to the isolated lung compartment to permit performance of the diagnostic test for collateral ventilation. The tests described in the previously incorporated patent applications generally rely on detecting flow from the isolated compartment or introducing gas into the isolated compartment in order to determine compliance. Thus, while used in the diagnostic or determining mode, it will usually be necessary that the flow restrictor have the ability to allow gas flow into and/or out of the compartment.
Flow restrictive elements or components which allow for flow therethrough can be provided in a number of ways. For example, the restrictive stents described in application Ser. No. 11/682,986 each have an orifice, lumen, or other flow channel present therein which can be relied on for gas exchange in the methods of the present invention. In the case of occlusive stents, it is possible to provide for a temporary orifice or flow path therethrough which can be sealed when the flow restrictive element is detached from the delivery catheter.
The present invention further provides functional assessment catheters comprising a catheter shaft and a flow restrictive component thereon. The catheter shaft has a distal end, a proximal end, and a central passage therebetween. The flow restrictive component is disposed on or at the distal end of the catheter shaft and has an expanded configuration and a contracted configuration.
In a first embodiment, a separate obturator is disposed in the central passage of the catheter shaft and is shiftable between a distally advanced position and a proximally retracted position. In the distally advanced position, the distal end of the obturator engages and elongates the flow restrictive component which causes the component to assume the contracted configuration. By proximally retracting the obturator, the flow restrictive component is allowed to resume or “spring back” to its expanded configuration. Thus, the flow restrictive component can be delivered to the bronchus feeding the lung compartment by first advancing the component in its contracted configuration with the obturator advanced and then deploying the component by retracting the obturator to allow the flow restrictive component to expand in situ at a desired location immediately upstream of the target lung compartment.
In this first embodiment, the functional assessment catheter may have a permanently attached flow restrictive element, in which case it is useful only for performing the diagnostic function and not for releasing the flow restrictive element to treat the patient. To use the catheter in a therapeutic situation, additional means for separating flow restrictive element from the catheter shaft would be provided.
In a second embodiment, a functional assessment and treatment catheter is specifically designed to permit release of the flow restrictive component from the catheter shaft. The flow restrictive component is secured to a distal end of the catheter shaft by a selective release mechanism. A wide variety of suitable selective release mechanisms are available, including mechanical mechanisms, such as screws, lock and release mechanisms, spiral screw mechanisms, shape memory release mechanisms, collets, latches, jaws, and the like. Electrical and electromechanical release mechanisms would also be available, including piezoelectric detachment mechanisms, electrical heating and expansion release mechanisms, and the like. Additionally, magnetic release mechanisms would be available. A variety of release mechanisms of the type used in embolic coil release would be useful in the release structures of the present invention. Such release mechanisms are described, for example, in U.S. Pat. Nos. RE37/117; 6,099,546; 5,800,455; and 5,624,449; the full disclosures of which are incorporated herein by reference.
In both the releasable and nonreleasable flow restrictive component embodiments, the flow restrictive component will preferably comprise a resilient scaffold having an elastomeric covering over at least a portion thereof. Usually, the resilient scaffold comprises counterwound helical supports formed from stainless steel, spring steel with coating, memory polymers, nickel-titanium alloys, and the like. The elastomeric covering can be formed from a variety of polymers, including silicones, polyurethanes, polyethylenes, polyvinylchlorides, and the like.
As shown in
The flow restrictive component 14 will normally be in an expanded configuration, as shown in
In the particular embodiment illustrated in
An obturator assembly 30 is provided in order to elongate and constrict the diameter of the flow restrictive component 14. The obturator assembly 30 comprises a flexible rod 32, typically a coiled wire formed from a metal or semi-rigid plastic material. Suitable metals include stainless steel, titanium, nickel-titanium alloy, or any other metal of the type conventionally used in construction of medical guidewires. Metal shafts may be coated with PTFE or other material in order to enhance the lubricity as it is introduced through a lumen of the shaft 12 into the interior of the flow restrictive component 14. A distal tip 33 engages the end cap 44 of the flow restrictive component 14, as best seen in
Referring now to
An exemplary release mechanism 158 for selectively detaching a flow restrictive component 154 from a catheter shaft 152 is illustrated in
Usually, a separate delivery sheath 60 will be provided for facilitating delivery of the flow restrictive component 54 of the catheter 50. The sheath 60 will have a diameter 60 suitable for introduction into the target bronchii, typically having an outer diameter in the range from 1 mm to 3 mm. The flow restrictive component 54 will be radially constrained and introduced through an interior lumen of the delivery sheath, simply by pushing the shaft 52 distally so that the constrained flow restrictive component 54 is advanced through the sheath 50 as shown in
Specific examples of flow restrictive elements suitable for permitting continued air exchange with the isolated lung compartment and controlled atelectasis and/or HPV are illustrated in
Referring now to
Each lung segment, also referred to as a bronchopulmonary segment, is an anatomically distinct unit or compartment of the lung which is fed air by a tertiary bronchus and which oxygenates blood through a tertiary artery. Normally, the lung segment and its surrounding fibrous septum are intact units which can be surgically removed or separated from the remainder of the lung without interrupting the function of the surrounding lung segments. In some patients, however, the fibrous septum separating the lobes or segments may be perforate or broken, thus allowing air flow between the segments, referred to as “collateral ventilation.”
Use of the delivery sheath 60 for placement of the flow restrictive component 54 in accordance with the principles of the present invention shown generally in
After the distal end 62 of the delivery sheath 60 has been positioned in the main airway or bronchus which feeds the diseased lung region DR, the sheath may be optionally immobilized by inflating a balloon or cuff 64 at or near the proximal end of the sheath 60. After immobilizing the distal end of the sheath, the catheter shaft 52 of catheter 50 may be distally advanced in order to deploy the flow restrictive component 54 into the feeding bronchus FB leading to the diseased lung region DR, as shown in
While the above is a complete description of the preferred embodiments of the invention, various alternatives, modifications, and equivalents may be used. Therefore, the above description should not be taken as limiting the scope of the invention which is defined by the appended claims.
This application is a divisional of U.S. patent application Ser. No. 11/845,296, filed Aug. 27, 2007, which claims priority to Provisional Application No. 60/823,734, filed Aug. 28, 2006, and Provisional Application No. 60/828,496, filed Oct. 6, 2006, the disclosures of which are incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
2230226 | Auzin | Feb 1941 | A |
4921484 | Hillstead | May 1990 | A |
5261916 | Engelson | Nov 1993 | A |
5304195 | Twyford, Jr. | Apr 1994 | A |
5624449 | Pham et al. | Apr 1997 | A |
5649906 | Gory et al. | Jul 1997 | A |
5749883 | Halpern | May 1998 | A |
5795322 | Boudewijn | Aug 1998 | A |
5800455 | Palermo et al. | Sep 1998 | A |
5895391 | Farnholtz | Apr 1999 | A |
6099546 | Gia | Aug 2000 | A |
6179860 | Fulton et al. | Jan 2001 | B1 |
RE37117 | Palermo | Mar 2001 | E |
6287290 | Perkins et al. | Sep 2001 | B1 |
6371971 | Tsugita et al. | Apr 2002 | B1 |
6527761 | Buch et al. | Mar 2003 | B1 |
6635068 | Dubrul et al. | Oct 2003 | B1 |
6679264 | Deem et al. | Jan 2004 | B1 |
6722360 | Doshi | Apr 2004 | B2 |
6941950 | Wilson et al. | Sep 2005 | B2 |
6958074 | Russell | Oct 2005 | B2 |
6997918 | Soltesz et al. | Feb 2006 | B2 |
7011094 | Rapacki et al. | Mar 2006 | B2 |
8342182 | Nair et al. | Jan 2013 | B2 |
20010037808 | Deem et al. | Nov 2001 | A1 |
20020143387 | Soetikno et al. | Oct 2002 | A1 |
20020169494 | Mertens et al. | Nov 2002 | A1 |
20030051733 | Kotmel | Mar 2003 | A1 |
20030154988 | DeVore et al. | Aug 2003 | A1 |
20040060563 | Rapacki et al. | Apr 2004 | A1 |
20040073191 | Soltesz et al. | Apr 2004 | A1 |
20040206349 | Alferness et al. | Oct 2004 | A1 |
20050288684 | Aronson et al. | Dec 2005 | A1 |
20060095002 | Soltesz et al. | May 2006 | A1 |
20060102186 | Adler | May 2006 | A1 |
20060122647 | Callaghan et al. | Jun 2006 | A1 |
20060135986 | Wallace | Jun 2006 | A1 |
20060264772 | Aljuri et al. | Nov 2006 | A1 |
20060271093 | Holman et al. | Nov 2006 | A1 |
20070005083 | Sabanathan et al. | Jan 2007 | A1 |
20070096048 | Clerc | May 2007 | A1 |
20070142742 | Aljuri et al. | Jun 2007 | A1 |
20070186933 | Domingo et al. | Aug 2007 | A1 |
20070225747 | Perkins et al. | Sep 2007 | A1 |
Number | Date | Country |
---|---|---|
0791340 | Aug 1997 | EP |
0815803 | Jan 1998 | EP |
WO 03022124 | Mar 2003 | WO |
WO 03022221 | Mar 2003 | WO |
WO 2006055692 | May 2006 | WO |
WO 2006078451 | Jul 2006 | WO |
Entry |
---|
Choostenttm, Covered Esophageal Stent, pp. 1-2, Jul. 26, 2005. |
European search report dated Jul. 28, 2009 fpr EP Application No. 07841495.0. |
International search report and written opinion dated Apr. 8, 2008 for PCT/US2007/077023. |
Office action dated Feb. 8, 2012 for U.S. Appl. No. 11/845,296. |
Office action dated Apr. 13, 2011 for U.S. Appl. No. 11/845,296. |
Number | Date | Country | |
---|---|---|---|
20130338524 A1 | Dec 2013 | US |
Number | Date | Country | |
---|---|---|---|
60828496 | Oct 2006 | US | |
60823734 | Aug 2006 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11845296 | Aug 2007 | US |
Child | 13689344 | US |